New York University's Clinical and Translational Science Institute (CTSI) has awarded an NYU nursing-dental research team a one-year pilot grant to assess the feasibility of using gingival crevicular blood from periodontal patients to gauge hemoglobin A1C -- a blood glucose measurement -- as a means of diagnosing diabetes and identifying pre-diabetes. CTSI is a partnership between New York University's Langone Medical Center and the New York City Health and Hospitals Corporation funded by a grant from the National Center for Research Resources of the NIH.
The hemoglobin A1C test has long been used to measure how well people already diagnosed with diabetes have their blood glucose levels under control. In January 2010, the American Diabetes Association issued new clinical practice recommendations calling for the addition of the hemoglobin A1C test as a means also of diagnosing diabetes and diabetic risk.
Led by Dr. Shiela Strauss, associate professor of nursing and Co-Director of the Statistics and Data Management Core for NYU's Colleges of Nursing and Dentistry, the study will gauge levels of hemoglobin A1C utilizing a version of an A1C testing kit that was initially developed specifically to enable dentists and dental hygienists to collect finger-stick blood samples and send them to a laboratory for analysis.
Dr. Strauss has adapted the testing kit to include oral blood as well as finger-stick samples. Using Dr. Strauss's adapted version of the test, oral healthcare providers can play a role in screening patients for diabetes without having to draw and analyze venous blood samples, a process requiring certification by the Centers for Medicare & Medicaid Services, a division of the US Department of Health and Human Services.
Dr. Strauss will recruit periodontal patients for the research because an earlier study that she led found that over 90 percent of people with periodontal disease but with undiagnosed diabetes are at
|Contact: Christopher James|
New York University